A Randomized, Phase II Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer.
Nemunaitis J. Genome Expression to Targeted Therapy in Cancer Management. Hereditary Genetics. May 2014; 3(2):129.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.
Randomized phase II study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Vertically Integrated Translational Studies of PDX1 as a Therapeutic Target for Pancreatic Cancer via a Novel Bifunctional RNAi Platform.
The most common way people give up their power is by thinking they don’t have any.
Nature, international scientific journal features immunotherapy results on Mary Crowley patient, Carley Rutledge.